Ticagrelor + Placebo
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Sickle Cell Disease
Conditions
Sickle Cell Disease
Trial Timeline
Jul 9, 2015 → Nov 16, 2016
NCT ID
NCT02482298About Ticagrelor + Placebo
Ticagrelor + Placebo is a phase 2 stage product being developed by AstraZeneca for Sickle Cell Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT02482298. Target conditions include Sickle Cell Disease.
What happened to similar drugs?
4 of 20 similar drugs in Sickle Cell Disease were approved
Approved (4) Terminated (9) Active (8)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (9)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03615924 | Phase 3 | Terminated |
| NCT03354429 | Phase 3 | Completed |
| NCT02482298 | Phase 2 | Completed |
| NCT02352402 | Phase 3 | UNKNOWN |
| NCT02110303 | Phase 2/3 | Completed |
| NCT02335099 | Phase 1/2 | Completed |
| NCT01998399 | Phase 2 | Terminated |
| NCT02070653 | Phase 2 | Completed |
| NCT01347580 | Approved | Completed |
Competing Products
20 competing products in Sickle Cell Disease